Switch theme
Sign up to access all valuation multiples
CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C and antibiotics.
1992
23.5K+
LTM Revenue $4.3B
LTM EBITDA $1.0B
$7.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CSPC Pharma Group has a last 12-month revenue of $4.3B and a last 12-month EBITDA of $1.0B.
In the most recent fiscal year, CSPC Pharma Group achieved revenue of $4.0B and an EBITDA of $1.1B.
CSPC Pharma Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CSPC Pharma Group valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $4.0B | $4.0B | XXX | XXX | XXX |
| Gross Profit | $2.7B | $2.9B | XXX | XXX | XXX |
| Gross Margin | 68% | 71% | XXX | XXX | XXX |
| EBITDA | $1.1B | $1.1B | XXX | XXX | XXX |
| EBITDA Margin | 28% | 27% | XXX | XXX | XXX |
| Net Profit | $721M | $783M | XXX | XXX | XXX |
| Net Margin | 18% | 19% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, CSPC Pharma Group's stock price is HKD 6 (or $1).
CSPC Pharma Group has current market cap of HKD 65.9B (or $8.5B), and EV of HKD 57.6B (or $7.4B).
See CSPC Pharma Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.4B | $8.5B | XXX | XXX | XXX | XXX | $0.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, CSPC Pharma Group has market cap of $8.5B and EV of $7.4B.
CSPC Pharma Group's trades at 1.8x LTM EV/Revenue multiple, and 7.6x LTM EBITDA.
Analysts estimate CSPC Pharma Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for CSPC Pharma Group and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $7.4B | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | 6.8x | XXX | XXX | XXX |
| P/E | 11.2x | XXX | XXX | XXX |
| P/E/Growth | -5.4x | XXX | XXX | XXX |
| EV/FCF | 25.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCSPC Pharma Group's NTM/LTM revenue growth is 4%
CSPC Pharma Group's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, CSPC Pharma Group's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate CSPC Pharma Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for CSPC Pharma Group and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -1% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 31% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 29% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 15% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 48% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CSPC Pharma Group acquired XXX companies to date.
Last acquisition by CSPC Pharma Group was XXXXXXXX, XXXXX XXXXX XXXXXX . CSPC Pharma Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was CSPC Pharma Group founded? | CSPC Pharma Group was founded in 1992. |
| Where is CSPC Pharma Group headquartered? | CSPC Pharma Group is headquartered in Hong Kong. |
| How many employees does CSPC Pharma Group have? | As of today, CSPC Pharma Group has 23.5K+ employees. |
| Who is the CEO of CSPC Pharma Group? | CSPC Pharma Group's CEO is Mr. Cuilong Zhang. |
| Is CSPC Pharma Group publicy listed? | Yes, CSPC Pharma Group is a public company listed on HKG. |
| What is the stock symbol of CSPC Pharma Group? | CSPC Pharma Group trades under 01093 ticker. |
| When did CSPC Pharma Group go public? | CSPC Pharma Group went public in 1994. |
| Who are competitors of CSPC Pharma Group? | Similar companies to CSPC Pharma Group include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of CSPC Pharma Group? | CSPC Pharma Group's current market cap is $8.5B |
| What is the current revenue of CSPC Pharma Group? | CSPC Pharma Group's last 12-month revenue is $4.3B. |
| What is the current EBITDA of CSPC Pharma Group? | CSPC Pharma Group's last 12-month EBITDA is $1.0B. |
| What is the current EV/Revenue multiple of CSPC Pharma Group? | Current revenue multiple of CSPC Pharma Group is 1.8x. |
| What is the current EV/EBITDA multiple of CSPC Pharma Group? | Current EBITDA multiple of CSPC Pharma Group is 7.6x. |
| What is the current revenue growth of CSPC Pharma Group? | CSPC Pharma Group revenue growth between 2023 and 2024 was 2%. |
| Is CSPC Pharma Group profitable? | Yes, CSPC Pharma Group is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
